Edition:
United States

Celyad SA (CYAD.BR)

CYAD.BR on Brussels Stock Exchange

25.70EUR
6:57am EDT
Change (% chg)

€1.22 (+4.98%)
Prev Close
€24.48
Open
€25.48
Day's High
€26.80
Day's Low
€24.96
Volume
135,467
Avg. Vol
48,889
52-wk High
€56.48
52-wk Low
€22.30

Chart for

About

Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company's product, C-Cure,... (more)

Overall

Beta: 1.98
Market Cap(Mil.): €281.97
Shares Outstanding(Mil.): 11.52
Dividend: --
Yield (%): --

Financials

  CYAD.BR Industry Sector
P/E (TTM): -- 243.17 32.94
EPS (TTM): -5.82 -- --
ROI: -57.19 -7.30 12.79
ROE: -81.48 -10.05 14.67

BRIEF-Celyad Announces Pricing Of 47.3 Million Dollars Global Offering

* 1,276,087 ORDINARY SHARES IN EUROPE AND CERTAIN COUNTRIES OUTSIDE OF US AND CANADA IN CONCURRENT PRIVATE PLACEMENT AT PRICE OF EUR 22.29PER SHARE

May 17 2018

BRIEF-Celyad Says Grade 4 Adverse Events Occurred In Two THINK Trial Patients, Announces Q1 Business Update

* GRADE 4 SERIOUS ADVERSE EVENTS OCCURRED IN TWO PATIENTS OF CYAD-01 THINK TRIAL OUT OF 20 PATIENTS INCLUDED IN INTERIM SAFETY REPORT

May 16 2018

BRIEF-Celyad Successfully Administers CYAD-01 In First Patients In Shrink And Link Trials

* CELYAD SUCCESSFULLY ADMINISTERS CYAD-01 IN FIRST PATIENTS IN SHRINK AND LINK TRIALS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

May 03 2018

BRIEF-Celyad's CYAD-01 Induced Complete Remission In Relapsed/Refractory AML Patient

* HAEMATOLOGICA PUBLISHES CELYAD THINK STUDY CASE REPORT OF CYAD-01 INDUCED COMPLETE REMISSION IN RELAPSED/REFRACTORY AML PATIENT

Apr 27 2018

BRIEF-Celyad To Present Updates On CYAD-01 At American Association For Cancer Research Annual Meeting

* CELYAD TO PRESENT UPDATES ON CYAD-01 AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2018

Mar 29 2018

Earnings vs. Estimates